Skip to main content
. Author manuscript; available in PMC: 2016 Feb 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 Oct 9;22(2):307–315. doi: 10.1016/j.bbmt.2015.10.002

Figure 6. Survival in HSCT recipients with high-risk TMA.

Figure 6

Survival curves for patients with high risk TMA who were treated with the terminal complement blocker eculizumab (“Treated”, n=18) and historical controls from prospective observational TMA study with the same high risk TMA features who did not receive eculizumab (“Historical Controls”, n=11) were calculated using Kaplan-Meier and the Log Rank test starting at TMA diagnosis to assess statistical significance. Patients with high risk TMA who received eculizumab therapy had better survival than untreated patients who historically are known to have nearly dismal outcome (56% versus 9% at 1 year from TMA diagnosis, p=0.003).